P3 Health Partners (PIII)
NASDAQ:PIII
Want to see PIII full AI Analyst Report?
Top Page
P3 Health Partners
(NASDAQ:PIII)
Select Model
Select Model
Rating:61Neutral
Price Target:
$11.50
▲(228.57% Upside)
Action:Reiterated
Date:06/11/26
The score is held back primarily by weak financial fundamentals (losses, negative equity, and negative cash flow). Offsetting this, the stock shows strong technical momentum and the latest earnings call signaled improving operating trajectory with raised adjusted EBITDA guidance, while recent corporate actions improved listing compliance and capital structure but add dilution considerations.
Positive Factors
Delegation & Provider Alignment
Moving a majority of membership to delegated contracts and concentrating care with Tier 1 providers is a durable operational advantage. It gives P3 greater clinical control and ability to manage utilization, speeds care-coordination efficiency, and makes contract economics more sustainable under risk arrangements.
Negative Factors
Negative Stockholders' Equity
Persistently negative stockholders' equity constrains financing options and raises solvency risk. Even with recent equity-strengthening actions, negative equity limits flexibility for growth investments, increases refinancing risk, and can complicate long-term partnerships and counterparty confidence.
Read all positive and negative factors
Positive Factors
Negative Factors
Delegation & Provider Alignment
Moving a majority of membership to delegated contracts and concentrating care with Tier 1 providers is a durable operational advantage. It gives P3 greater clinical control and ability to manage utilization, speeds care-coordination efficiency, and makes contract economics more sustainable under risk arrangements.
Read all positive factors
P3 Health Partners (PIII) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$77.88M
Dividend YieldN/A
Average Volume (3M)7.40K
Price to Earnings (P/E)―
Beta (1Y)0.08
Revenue Growth-0.87%
EPS Growth10.51%
CountryUS
Employees360
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-38.55
Shares Outstanding3,325,858
10 Day Avg. Volume4,406
30 Day Avg. Volume7,400
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.07
Price to Sales (P/S)0.00782
P/FCF Ratio-0.13
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue0.05
Enterprise Value/Gross Profit0.10
Enterprise Value/Ebitda-0.53
Forecast
1Y Price Target
$488.00Price Target Upside13842.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-8.08
Revenue Forecast (FY)$1.52B
P3 Health Partners Business Overview & Revenue Model
Company Description
P3 Health Partners Inc. is a population health management enterprise that delivers exceptional, patient-centered care throughout the United States. Guided by physician leadership, this company manages a network of clinics and wellness centers. Its...
How the Company Makes Money
P3 Health Partners generates revenue primarily through value-based care arrangements tied to Medicare Advantage and other risk-based contracts. Under these models, P3 (directly or through affiliated entities) is paid to manage the medical care of ...
P3 Health Partners Earnings Call Summary
Earnings Call Date:May 14, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Positive
The call conveyed a materially improved operating trajectory with a clear shift to positive adjusted EBITDA, stronger Medicare Advantage funding (~15% YoY), deeper provider alignment (Tier 1 up to 62%) and disciplined cost management producing a flat MA medical trend versus industry inflation. These operational and contractual wins supported a raised outlook and meaningful capital structure actions that improve equity compliance. Counterbalancing these positives were a roughly 10% decline in at-risk membership (by design), limited cash ($25M), reliance on $17M of favorable prior-year development (underlying adjusted EBITDA ~$8M), a relatively high adjusted medical loss ratio (~85.2%), and continued execution risk tied to achieving broader delegation and managing claims development. On balance, the quarter demonstrates improving fundamentals and credible progress, while still requiring execution on multi-year delegation and capital stability initiatives.Positive Updates
Adjusted EBITDA Turnaround
Delivered $26 million of adjusted EBITDA in Q1 2026, exceeding internal expectations and improving from a loss of $22 million in Q1 2025, demonstrating a substantial swing to positive operating performance.
Negative Updates
Decline in At-Risk Membership
At-risk membership declined to ~106,000 at the end of Q1 2026 from 118,000 in Q1 2025 (≈10% decline), driven by deliberate exits of arrangements that did not meet economic thresholds, reducing scale in the near term.
Read all updates
Q1-2026 Updates
Positive
Negative
Adjusted EBITDA Turnaround
Delivered $26 million of adjusted EBITDA in Q1 2026, exceeding internal expectations and improving from a loss of $22 million in Q1 2025, demonstrating a substantial swing to positive operating performance.
Read all positive updates
Company Guidance
Management raised full‑year 2026 adjusted EBITDA guidance to $20–$60 million (midpoint $40M) after a strong Q1 that delivered $26M of adjusted EBITDA ($8M underlying excluding ~$17M of favorable prior‑year development and payer settlements, ~65/35 split), revenue of $386M, medical claims expense of $306M, medical margin of $74M and adjusted operating expense of $25M. At‑risk membership was ~106,000 (vs. 118,000 in Q1‑2025) plus ~29,000 lives under management for ~135,000 total, MA funding per member improved ~15% YoY, delegated functions expanded to ~63% of membership, Nebraska added ~28,600 lives, cash was $25M, and a ~$250M debt→preferred conversion (plus up to $70M preferred issuance, $30M issued to date) materially strengthened equity; Q1 MA medical cost trend was roughly flat to the 2025 baseline (2025 full‑year MA/ACO trend <2%), and the guidance range reflects normal claims development and cost‑trend variability.P3 Health Partners Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
18
Very Negative
Cash Flow
16
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.47B | 1.46B | 1.50B | 1.27B | 1.05B | 637.36M |
| Gross Profit | 745.36M | -144.32M | 1.50B | 1.27B | 1.05B | -30.70M |
| EBITDA | -138.59M | -186.14M | -197.76M | -81.07M | -1.46B | -184.61M |
| Net Income | -126.25M | -147.95M | -135.85M | -57.77M | -270.13M | -156.48M |
Balance Sheet | ||||||
| Total Assets | 674.16M | 656.64M | 783.42M | 860.97M | 876.74M | 2.36B |
| Cash, Cash Equivalents and Short-Term Investments | 25.50M | 25.01M | 38.82M | 36.32M | 18.46M | 140.48M |
| Total Debt | 62.27M | 284.88M | 166.16M | 124.64M | 107.54M | 92.02M |
| Total Liabilities | 807.32M | 796.88M | 633.89M | 427.31M | 354.08M | 299.94M |
| Stockholders Equity | -143.55M | -155.23M | 75.94M | 142.13M | 5.85M | 273.55M |
Cash Flow | ||||||
| Free Cash Flow | -85.16M | -91.16M | -110.13M | -77.86M | -128.25M | -69.88M |
| Operating Cash Flow | -85.24M | -91.24M | -110.13M | -76.03M | -126.02M | -66.47M |
| Investing Cash Flow | 86.00K | 129.00K | 14.53M | -1.83M | -7.73M | -56.07M |
| Financing Cash Flow | 69.96M | 72.81M | 98.77M | 100.33M | 11.38M | 223.47M |
P3 Health Partners Technical Analysis
Neutral
3.50
Price Trends
7.38
Positive
4.93
Positive
5.77
Positive
Market Momentum
1.05
Positive
50.70
Neutral
21.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PIII, the sentiment is Neutral. The current price of 3.5 is below the 20-day moving average (MA) of 12.61, below the 50-day MA of 7.38, and below the 200-day MA of 5.77, indicating a neutral trend. The MACD of 1.05 indicates Positive momentum. The RSI at 50.70 is Neutral, neither overbought nor oversold. The STOCH value of 21.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PIII.
P3 Health Partners Risk Analysis
P3 Health Partners disclosed 58 risk factors in its most recent earnings report. P3 Health Partners reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
P3 Health Partners Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $1.16B | 38.30 | 9.23% | ― | 36.76% | 11.22% | |
61 Neutral | $77.88M | -0.28 | 184.97% | ― | -0.87% | 10.51% | |
58 Neutral | $1.90B | -5.06 | -146.01% | ― | -2.82% | -45.70% | |
55 Neutral | $525.91M | -123.06 | 326.77% | ― | 35.37% | 46.10% | |
55 Neutral | $1.22B | -54.83 | -9.20% | ― | 14.13% | 62.92% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $51.72M | ― | -88.97% | ― | -42.03% | -28904.55% |
* Healthcare Sector Average
PIII
P3 Health Partners
10.75
4.50
72.00%
PNTG
Pennant Group
33.44
5.66
20.37%
TOI
Oncology Institute
5.26
2.87
120.08%
DCGO
DocGo
0.52
-1.07
-67.11%
INNV
InnovAge Holding
8.97
5.08
130.59%
AGL
Agilon Health
113.80
59.30
108.81%
P3 Health Partners Corporate Events
Executive/Board ChangesPrivate Placements and FinancingShareholder Meetings
P3 Health Partners Stockholders Back Board, Warrants Proposal
Positive
Jun 10, 2026
On June 9, 2026, P3 Health Partners Inc. held its 2026 Annual Meeting of Stockholders, where holders of Class A and Class V common stock voted on board elections and key corporate matters. Stockholders elected three Class II directors, Amir Bacchu...
Delistings and Listing ChangesRegulatory Filings and Compliance
P3 Health Partners Regains Full Nasdaq Listing Compliance
Positive
May 26, 2026
On November 28, 2025, P3 Health Partners Inc. disclosed that it had received a deficiency notice from Nasdaq, stating the company did not meet at least one of the continued listing standards related to minimum stockholders’ equity, market va...
Delistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
P3 Health Partners Executes Debt Exchange to Bolster Equity
Positive
May 15, 2026
P3 Health Partners Inc., a value-based healthcare services provider focused on managed care for senior and other health plan populations, operates through P3 Health Group, LLC and other subsidiaries to deliver coordinated clinical services under r...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
P3 Health Partners Restructures Debt and Raises New Capital
Positive
Apr 28, 2026
On April 27, 2026, P3 Health Partners Inc. and its subsidiary P3 Health Group, LLC entered into a Debt Exchange Agreement with affiliates of Chicago Pacific Founders, converting approximately $252.5 million of outstanding promissory notes into mul...
Business Operations and Strategy
P3 Health Partners Signs Long-Term Medicare Advantage Insurer Deal
Positive
Mar 25, 2026
On March 19, 2026, P3 Health Partners entered into a long-term Statement of Work and related Master Services Agreement with a large nonprofit health insurer in Nebraska to support primary care providers in the insurer’s Medicare Advantage ne...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.